Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

OptiBiotix Health unveils second distribution deal of the week for weight management product

It is teaming up with South Africa’s Formulation Creations, led by Gary Coulson, an industry expert with an “extensive network of customers and partners” in his local market
woman shows her waist has shrunk by holding open top of her jeans
The company's products help tackle obesity, high cholesterol and diabetes

OptiBiotix Health plc (LON:OPTI) has unveiled its second distribution agreement of the week for the company’s weight management product SlimBiome.

It has inked a deal with South Africa’s Formulation Creations, led by Gary Coulson, an industry expert with an “extensive network of customers and partners” in his local market.

Formulation already has partnerships with Gold Coast Ingredients, Real Stevia and Cambridge Commodities, OptiBiotix's UK distributor for SlimBiome.

“With such a wealth of local knowledge and technical expertise in the health and wellness sector, we are in a great position to offer the South African market bespoke concepts and weight management products to meet the demands of the local population,” said sales and marketing director Christina Wood.

News flow continues 

This is the AIM-listed group’s fourth piece of material news in ten days.

On Monday OptiBiotix said it had partnered with privately-owned functional foods business CTC Group, which will sell SlimBiome in the Philippines, Vietnam, Indonesia and Colombia.

The tie-up followed hard on the heels of a distribution agreement for its cholesterol product, CholBiome, and news that the group plans to spin out ProBiotix business.

OptiBiotix is a pioneer of the human microbiome, which is essentially the bacteria that inhabit the gut and skin.

It has found, for instance, small changes in the gut flora can affect the way the human body processes food.

Its products are focused on tackling obesity, diabetes and cholesterol.

View full OPTI profile View Profile

OptiBiotix Health plc Timeline

Related Articles

myLotus kit
August 06 2018
The expansion drive is targeting an estimated 2.3mln women per year in the areas of Hebei, Shanghai, Beijing, Shangdong, Henan and Liaoning
1511901712_biotech_517925923.jpg
November 29 2017
The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.
picture of addict
November 15 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use